Login / Register 
United States ($) USD
Austria (€) EUR
Belgium (€) EUR
Finland (€) EUR
France (€) EUR
Germany (€) EUR
Ireland (€) EUR
Japan (¥) JPY
Luxembourg (€) EUR
Netherlands (€) EUR
Switzerland (CHF) CHF
United Kingdom (£) GBP
- Regulatory Status
- RUO
- Other Names
- Lymphocyte activation gene 3 protein, LAG-3, Secretedlymphocyte activation gene 3 protein, sLAG3, CD223
- Ave. Rating
- Submit a Review
- Product Citations
- publications
-
Recombinant Human CD223 (LAG-3)-Fc Chimera induces TNFα secretion in JAWSII cells in a dose-dependent manner. EC50 of this effect is 0.4 - 2.4 µg/mL. -
Stability testing for recombinant human CD223 (LAG-3)-Fc Chimera. Recombinant Human CD223 (LAG3)-Fc Chimera was aliquoted in PBS, pH 7.2, at 0.2 mg/mL and one aliquot was kept at 4°C (Control), and another was frozen and thawed four times (4x Freeze/Thaw). After this procedure, the samples were tested for their ability to induce TNFα secretion in JAWSII cells in a dose-dependent manner. The EC50 for this effect is 0.4 - 2.4 µg/mL.
| Cat # | Size | Price | Quantity Check Availability | Save | ||
|---|---|---|---|---|---|---|
| 596404 | 25 µg | 390 CHF | ||||
| 596406 | 100 µg | 695 CHF | ||||
Initially documented in the 1990, lymphocyte activation gene 3 (LAG3, CD223) is an inhibitory co-receptor of the type-1 immunoglobulin family with a molecular mass of 50 kD. LAG3 exhibits four extracellular immunoglobulin-like domains named D1 to D4, a transmembrane region and an intracellular region. Except the proline-rich loop located on D1, LAG3 is structurally similar to the CD4 co-receptor. LAG3 selectively interacts with the major histocompatibility complex class II (MHC II) of antigen presenting cells (APCs) and tumor cells which activates the inhibitory pathway and eventually lead to dysfunction of T-cells. LAG3 receptors and their ligands are expressed in the tumor microenvironment and form a complex organization for cell-communication. LAG3 receptors are present on almost all T-lymphocytes (activated CD4+ T-cells, CD8+ T-cells, FOXP3+ regulatory T-cells and Naïve T-cells), NK cells and dendritic cells (DCs). Dendritic cells express both LAG3 receptors and their ligands and LAG3 induced signaling promotes their maturation. LAG3 acts synergistically with PD-1 and/or other immunoregulatory genes to prevent autoimmunity in mice. The infiltrated LAG3+ lymphocytes are associated with overall survival of TNBC and HER2+ breast cancer patients, in addition, peripheral blood LAG3+ immunotype strongly corelates with treatment responses, survival, progression-free survival in melanoma. Current existing clinical therapeutic agents targeting LAG3 can be classified into three different groups; the LAG3 fusion protein, the LAG3 monoclonal antibody and the LAG3 involving bispecific antibody. A novel combinatorial FDA approved immunotherapy uses LAG3 blocking agent together with nivolumab (anti-PD-1 agent) for metastatic melanoma’ which may suggest future prospects of LAG3 targeted therapies for cancer patients.
Product DetailsProduct Details
- Source
- Human CD223 (LAG-3)-Fc Chimera, amino acids Leu23-Leu450 (Accession # P18627), with a C-terminal hIgG1-Fc tag, was expressed in 293E cells.
- Molecular Mass
- The 664 amino acid recombinant protein has a predicted molecular mass of approximately 74.8 kD. The DTT-reduced and non-reduced protein migrate at approximately 70-80 kD and 140-150 kD respectively in SDS-PAGE.
-
N-terminal
Sequence Analysis - The predicted N-terminal amino acid is Leu.
- Purity
- > 95%, as determined by Coomassie stained SDS-PAGE.
- Formulation
- 0.22 µm filtered protein solution is in PBS, pH 7.2
- Endotoxin Level
- Less than 0.1 EU per μg of cytokine as determined by the LAL method
- Concentration
- 25 µg size is bottled at 200 µg/mL. 100 µg size and larger sizes are lot-specific and bottled at the concentration indicated on the vial. To obtain lot-specific concentration and expiration, please enter the lot number in our Certificate of Analysis online tool.
- Storage & Handling
- Unopened vial can be stored between 2°C and 8°C for up to 2 weeks, at -20°C for up to six months, or at -70°C or colder until the expiration date. For maximum results, quick spin the vial prior to opening. The protein can be aliquoted and stored at -20°C or colder. Stock solutions can also be prepared at 50 - 100 µg/mL in appropriate sterile buffer, carrier protein such as 0.2 - 1% BSA or HSA can be added when preparing the stock solution. Aliquots can be stored between 2°C and 8°C for up to one week and stored at -20°C or colder for up to 3 months. Avoid repeated freeze/thaw cycles.
- Activity
- Recombinant Human CD223 (LAG-3)-Fc Chimera induces TNFα secretion in JAWSII cells in a dose-dependent manner. EC50 of this effect is 0.4 - 2.4 µg/mL.
- Application
-
Bioassay
- Application Notes
-
BioLegend carrier-free recombinant proteins provided in liquid format are shipped on blue-ice. Our comparison testing data indicates that when handled and stored as recommended, the liquid format has equal or better stability and shelf-life compared to commercially available lyophilized proteins after reconstitution. Our liquid proteins are validated in-house to maintain activity after shipping on blue ice and are backed by our 100% satisfaction guarantee. If you have any concerns, contact us at tech@biolegend.com.
Antigen Details
- Structure
- Monomer
- Distribution
-
T-lymphocytes, NK cells and dendritic cells (DCs)
- Function
- T-cell dysfunction, dendritic cell maturation, role in autoimmunity
- Interaction
- All T-lymphocytes (activated CD4+ T-cells, CD8+ T-cells, FOXP3+ regulatory T-cells and Naïve T-cells), NK cells and dendritic cells (DCs), antigen presenting cells (APCs) and tumor cells
- Ligand/Receptor
- MHC II of antigen presenting cells (APCs) and tumor cells
- Bioactivity
- Recombinant Human CD223 (LAG-3)-Fc Chimera induces TNFα secretion in JAWSII cells in a dose-dependent manner. EC50 of this effect is 0.4 - 2.4 µg/mL.
- Cell Type
- Dendritic cells, NK cells, T cells, Tregs
- Biology Area
- Immunology, Inhibitory Molecules
- Molecular Family
- CD Molecules, Immune Checkpoint Receptors
- Antigen References
-
- Triebel F, et al. 1990. J Exp Med. 171:1393-405.
- Chocarro L, et al. 2021. Int J Mol Sci. 17:5282.
- Gaikwad S, et al. 2022. Semin Cancer Biol. 86:137-150.
- Avice MN, et al. 1999. J Immunol. 162:2748-53.
- Lecocq Q, et al. 2020. Int J Mol Sci. 22:75.
- Mair MJ, et al. 2021. J Neurooncol. 152:533.
- Datar I, et al 2019. Clin Cancer Res. 25:4663-4673.
- Zeng H, et al. 2020. J. Immunother. Cancer. 8:e000651.
- Andreae S, et al. 2003. Blood. 102:2130-7.
- Okazaki T, et al. 2011. J Exp Med. 208:395-407.
- Guoming H, et al. 2023. Front Oncol. 12:986903.
- Shen R, et al. 2021. Sci Transl Med. 13:eabf5107.
- Gene ID
- 3902 View all products for this Gene ID
- UniProt
- View information about CD223 on UniProt.org
Related Pages & Pathways
Pathways
Related FAQs
- Why choose BioLegend recombinant proteins?
-
• Each lot of product is quality-tested for bioactivity as indicated on the data sheet.
• Greater than 95% Purity or higher, tested on every lot of product.
• 100% Satisfaction Guarantee for quality performance, stability, and consistency.
• Ready-to-use liquid format saves time and reduces challenges associated with reconstitution.
• Bulk and customization available. Contact us.
• Learn more about our Recombinant Proteins. - How does the activity of your recombinant proteins compare to competitors?
-
We quality control each and every lot of recombinant protein. Not only do we check its bioactivity, but we also compare it against other commercially available recombinant proteins. We make sure each recombinant protein’s activity is at least as good as or better than the competition’s. In order to provide you with the best possible product, we ensure that our testing process is rigorous and thorough. If you’re curious and eager to make the switch to BioLegend recombinants, contact your sales representative today!
- What is the specific activity or ED50 of my recombinant protein?
-
The specific activity range of the protein is indicated on the product datasheets. Because the exact activity values on a per unit basis can largely fluctuate depending on a number of factors, including the nature of the assay, cell density, age of cells/passage number, culture media used, and end user technique, the specific activity is best defined as a range and we guarantee the specific activity of all our lots will be within the range indicated on the datasheet. Please note this only applies to recombinants labeled for use in bioassays. ELISA standard recombinant proteins are not recommended for bioassay usage as they are not tested for these applications.
- Have your recombinants been tested for stability?
-
Our testing shows that the recombinant proteins are able to withstand room temperature for a week without losing activity. In addition the recombinant proteins were also found to withstand four cycles of freeze and thaw without losing activity.
- Does specific activity of a recombinant protein vary between lots?
-
Specific activity will vary for each lot and for the type of experiment that is done to validate it, but all passed lots will have activity within the established ED50 range for the product and we guarantee that our products will have lot-to-lot consistency. Please conduct an experiment-specific validation to find the optimal ED50 for your system.
- How do you convert activity as an ED50 in ng/ml to a specific activity in Units/mg?
-
Use formula Specific activity (Units/mg) = 10^6/ ED50 (ng/mL)
Follow Us